Clinical trial
Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B…
NCT00289744 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00289744 |
|---|---|
| Title | Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule |
| Official title | Long-Term Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Children |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B, Hepatitis A |
| Intervention type | Biological |
| Interventions | TWINRIX™ ADULT, Engerix TM |
| Enrollment | 178 |
| Start date | Feb 16, 2004 |
| Primary completion | Apr 15, 2009 |
| Completion | Apr 15, 2009 |
| First posted | Feb 10, 2006 |
| Last update posted | Aug 20, 2018 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: